Angus Liu
FiercePharma
Washington, DC, United States
Contact Angus
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Angus:
AstraZeneca’s Imfinzi, Tagrisso deliver lung cancer trial wins. For one, a Keytruda showdown looms
Two important oncology drugs for AstraZeneca have returned with trial wins in early-stage non-small cell lung cancer (NSCLC). | AstraZeneca reported two trial wins in early-stage non-small cell lung cancer. For the immunotherapy Imfinzi, the detailed data will feed into an increasingly fierce market showdown. → Read More
AZ, Daiichi's Enhertu posts trial win in numerous cancer types. Is a tumor-agnostic approval next?
Already approved in breast, stomach and lung cancers, AstraZeneca and Daiichi Sankyo’s Enhertu has delivered a trial win across many other tumor types that express the HER2 protein biomarker. | Already approved in breast, stomach and lung cancers, AstraZeneca and Daiichi Sankyo’s Enhertu has delivered a trial win across many other tumor types that express the HER2 protein biomarker. → Read More
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
After several market withdrawals, the FDA’s scrutiny around the PARP inhibitor class of cancer drugs doesn't seem to be abating. | After several market withdrawals, the FDA’s scrutiny around the PARP inhibitor class of cancer drugs doesn't seem to be abating. The agency will gather an advisory committee to review AstraZeneca and Merck & Co.’s application for Lynparza in prostate cancer. → Read More
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Under a new analysis, ICER says Eisai should take 19% to 66% off Leqembi’s current list price of $26,500. → Read More
BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches
Thanks to cancer drugs Brukinsa and tislelizumab, BeiGene nearly doubled its global sales in 2022. But the most important launches for the meds either have just begun or are yet to come. | Thanks to cancer drugs Brukinsa and tislelizumab, BeiGene nearly doubled its sales in 2022. But the most important launches for the meds have either just begun or are yet to come. → Read More
CDMO giant Catalent draws buyout interest from Danaher: Bloomberg
Contract biopharma manufacturer Catalent has reportedly drawn buyout interest as COVID-related declines weigh on its outlook and stock performance. → Read More
Roche taps insider Graham for top pharma job as setbacks prompt M&A questions
Even as Roche’s pharma group prepares for further biosimilar erosion, a decline in COVID-19 product revenues and key readouts, it’s welcoming a new leader. | Roche has found its new pharma CEO from within. She’ll lead a group that’s preparing for further biosimilar erosion, plus a decline from COVID-19 products and key clinical readouts. → Read More
In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion
It’s unusual to have the FDA chase down a pharma company and ask them apply for a new drug indication. | In an unusual move, the FDA requested an expanded approval of breast cancer drug Ibrance from Pfizer. And the New York pharma won the go-ahead without additional clinical efficacy data. → Read More
Bristol Myers makes case for Breyanzi in chronic lymphocytic leukemia. Will it make a difference?
CAR-T therapies have shown impressive results in acute lymphoblastic leukemia. | Bristol Myers Squibb aims to make Breyanzi the first CAR-T therapy for chronic lymphocytic leukemia. But without specifics, it remains unclear whether Breyanzi will bring meaningful advancement in this indication. → Read More
Bayer chairman under fire for lack of spinoff activity amid renewed investor activism
The push for a business separation at Bayer just got more personal. | The push for a business separation at Bayer just got more personal. Joining the chorus calling for a more focused Bayer, Union Investment portfolio manager Markus Manns criticized Bayer Chairman Norbert Winkeljohann. → Read More
Look out, AbbVie and J&J. BeiGene's Brukinsa just scored a key leukemia nod to take on Imbruvica
Armed with a new FDA approval in chronic lymphocytic leukemia (CLL), BeiGene is readying an all-out assault against AbbVie and Johnson & Johnson’s entrenched Imbruvica. | Armed with a new FDA approval in chronic lymphocytic leukemia, BeiGene is readying an all-out assault against AbbVie and Johnson & Johnson's entrenched Imbruvica. → Read More
JPM23: BMS touts 'diversified' portfolio as launches kick into gear and old drugs near patent cliff
By BMS’ estimates, about 50% of its revenue in 2030 will come from acquisitions, including its Celgene takeover. → Read More
AstraZeneca, Sanofi tee up 3-way RSV battle in 2023 as FDA signals expedited review for antibody
Thanks to the FDA’s expedited reviews, an RSV prevention market battle between several pharma giants may kick off in 2023. | Thanks to the FDA’s expedited reviews, an RSV prevention market battle between several pharma giants may kick off in 2023. → Read More
Novartis pays $245M to settle Exforge generic pay-for-delay lawsuit
Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. | Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. The lawsuit centered on an agreement Novartis and Endo's Par signed in 2011 that allegedly pushed back the launch of a copycat to Novartis' Exforge. → Read More
Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard
Despite five years of collective experience making and selling engineered human cell products, CAR-T companies are still having trouble ensuring smooth and timely access. For this report, Fierce Pharma talked to cell therapy leaders at three top cancer centers to understand how recent CAR-T launches are progressing in the real world. → Read More
Amgen, J&J and Sanofi size up Horizon as Big Pharma renews interest in rare disease M&A
As Big Pharma companies face growing competitive pressures for their existing businesses, they’ve been increasingly drawn to rare disease M&A. | Rare disease drug maker Horizon Therapeutics said it has drawn buyout interest from pharma juggernauts Amgen, Johnson & Johnson and Sanofi, all of which arguably have good reasons to make an M&A move. → Read More
ASH: AbbVie, J&J's Imbruvica under serious threat as BeiGene's Brukinsa delivers head-to-head trial win
BeiGene has shared detailed results from a Brukinsa head-to-head trial, and it’s bad news for rival Imbruvica from AbbVie and Johnson & Johnson. The latest update makes Brukinsa the first BTK inhibitor to top Imbruvica on a hard efficacy endpoint. → Read More
J&J vet Mammen wanted board influence to be Biogen's next CEO, but chairman said no: Stat
A top candidate to succeed Biogen CEO Michel Vounatsos is reportedly out of the running. | The talks over whether Johnson & Johnson veteran Mathai Mammen would become Biogen's next CEO have reportedly fallen through. The R&D exec demanded influence over Biogen's board, a proposal that was met with cold shoulder by current Chairman Stelios Papadopoulos, Stat reports. → Read More
COVID-19 tracker: Tens of millions of Bharat Biotech shots could expire
Tens of millions of doses of Bharat Biotech's Covaxin could expire in early 2023 because of low demand. | Tens of millions of doses of Bharat Biotech's Covaxin could expire in early 2023 because of low demand. BioNTech's third-quarter revenues fell 43% year over year. Plus more. → Read More
UPDATED: J&J's BCMA bispecific Tecvayli wins FDA approval in multiple myeloma—but as a late-line therapy
The FDA has granted an accelerated approval for Tecvayli, or teclistamab, for relapsed or refractory multiple myeloma. → Read More